Scott Thomas Jackson - 05 Dec 2025 Form 4 Insider Report for Mural Oncology plc (MURA)

Role: Director
Signature: /s/ Scott Thomas Jackson
Issuer symbol: MURA
Transactions as of: 05 Dec 2025
Net transactions value: $0
Form type: 4
Filing time: 05 Dec 2025, 09:01:56 UTC
Previous filing: 16 Jun 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Jackson Scott Thomas	Director	C/O MURAL ONCOLOGY PLC, 10 EARLSFORT TERRACE, DUBLIN 2, IRELAND	/s/ Scott Thomas Jackson	05 Dec 2025	0001566617

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Shares	Change %	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	MURA	Stock Option (right to buy)	Disposed to Issuer	-8,637	-100%	05 Dec 2025	Ordinary Shares	8,637	$2.56	Direct	F1, F2
transaction	MURA	Stock Option (right to buy)	Disposed to Issuer	-8,462	-100%	05 Dec 2025	Ordinary Shares	8,462	$3.35	Direct	F2
transaction	MURA	Stock Option (right to buy)	Disposed to Issuer	-15,021	-100%	05 Dec 2025	Ordinary Shares	15,021	$3.61	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Scott Thomas Jackson is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id	Content
F1	This Form 4 reports securities disposed of pursuant to the terms of the Transaction Agreement (the "Agreement"), dated August 20, 2025, by and among the Issuer, XRA 5 Corp. ("Sub"), a Delaware corporation and wholly-owned subsidiary of XOMA Royalty Corporation, a Nevada corporation, pursuant to which Sub acquired all the issued and to be issued share capital of the Issuer (the "Acquisition") for a cash purchase price of $2.035 per share (the "Scheme Consideration"). The Acquisition was completed as of December 5, 2025 (the "Effective Time").
F2	Pursuant to the terms of the Agreement, at the Effective Time each option to purchase ordinary shares of Issuer that had an exercise price per share that was equal to or greater than the Scheme Consideration was cancelled and ceased to be outstanding, and no Scheme Consideration was delivered in exchange for such options.

Content

This Form 4 reports securities disposed of pursuant to the terms of the Transaction Agreement (the "Agreement"), dated August 20, 2025, by and among the Issuer, XRA 5 Corp. ("Sub"), a Delaware corporation and wholly-owned subsidiary of XOMA Royalty Corporation, a Nevada corporation, pursuant to which Sub acquired all the issued and to be issued share capital of the Issuer (the "Acquisition") for a cash purchase price of $2.035 per share (the "Scheme Consideration"). The Acquisition was completed as of December 5, 2025 (the "Effective Time").

Pursuant to the terms of the Agreement, at the Effective Time each option to purchase ordinary shares of Issuer that had an exercise price per share that was equal to or greater than the Scheme Consideration was cancelled and ceased to be outstanding, and no Scheme Consideration was delivered in exchange for such options.